Co-Authors
This is a "connection" page, showing publications co-authored by Robert Fowler and Hanan Balkhy.
Connection Strength
1.146
-
Middle East Respiratory Syndrome. N Engl J Med. 2017 02 09; 376(6):584-594.
Score: 0.176
-
Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians. BMC Anesthesiol. 2016 07 12; 16(1):36.
Score: 0.169
-
The search for therapeutic options for Middle East Respiratory Syndrome (MERS). J Infect Public Health. 2016 May-Jun; 9(3):213-5.
Score: 0.166
-
Proceedings of the Middle East Respiratory Syndrome (MERS) Coronavirus research initiative workshop, September 9-10 2015 in Riyadh, KSA. J Infect Public Health. 2016 May-Jun; 9(3):205-7.
Score: 0.166
-
Knowledge gaps in therapeutic and non-therapeutic research on the Middle East respiratory syndrome. Lancet Respir Med. 2016 Feb; 4(2):93-4.
Score: 0.164
-
Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. N Engl J Med. 2020 10 22; 383(17):1645-1656.
Score: 0.057
-
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-ß1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020 Jan 03; 21(1):8.
Score: 0.054
-
Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. Influenza Other Respir Viruses. 2019 07; 13(4):382-390.
Score: 0.051
-
Macrolides in critically ill patients with Middle East Respiratory Syndrome. Int J Infect Dis. 2019 Apr; 81:184-190.
Score: 0.050
-
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018 03 15; 197(6):757-767.
Score: 0.047
-
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-ß1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 30; 19(1):81.
Score: 0.047